Executive summary

This study compared the bowel function (BF), urinary irritative/obstructive symptoms (UO), and urinary incontinence (UI) domains of EPIC-26 collected in 262 patients with T1-T2 prostate cancer receied IMRT (157 patients) or PBT (105 patients). At 3 months post-radiotherapy, the IMRT group had significant and clinically meaningful worsening of BF (-9.3, P < .001). There were no significant or clinically meaningful changes in UO or UI 3 months post-radiotherapy. This study concluded that PBT had less acute decrement in BF than IMRT following radiotherapy.

Key content topics
Top cancer treatments